New study tracks breast cancer treatments after drugs stop working

NCT ID NCT07407439

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This real-world study follows 245 people with HR+/HER2- advanced breast cancer who are taking CDK4/6 inhibitors combined with hormone therapy. Researchers want to see how long the treatment controls the cancer and what options work best after the cancer becomes resistant. The goal is to provide practical guidance for doctors treating patients in similar situations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib, dalpiciclib) combined with endocrine therapy
What this could lead to
If successful, this study could help doctors choose better treatments for patients whose cancer stops responding to CDK4/6 inhibitors.
What could go wrong
This is an observational study, not a controlled trial, so results may not apply to all patients. It only looks back at medical records from one hospital, which limits how widely the findings can be used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianjin Medical University Cancer Insititute and Hospital

    RECRUITING

    Tianjin, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.